U.S.-Japan trade pact; Alphabet, Tesla to report - what’s moving markets
Investing.com -- Bruker Corporation (NASDAQ:BRKR) shares tumbled 8.75% in pre-market trading on Monday after the scientific instruments maker reported preliminary second quarter results showing flat reported revenue and declining adjusted earnings amid weak academic demand and softness in the U.S. biopharma market.
The company announced preliminary revenue for the second quarter ended June 30, 2025, in a range of $795-$798 million, which is approximately flat on a reported basis compared to the same period last year.
However, Bruker estimates that its adjusted organic revenue declined approximately 7% YoY, with constant-exchange rate revenue declining approximately 3%.
Bruker expects second quarter 2025 adjusted EPS in the range of $0.32-$0.34, representing approximately a $0.19 per share decline YoY, which includes a $0.06 foreign currency headwind.
The disappointing results were attributed to weak academic demand and softness in the U.S. biopharma market during the quarter, which negatively impacted bookings.
"Our second quarter performance reflects the challenging market conditions we’re experiencing in our key segments," said a company executive. "The combination of academic spending constraints and biopharma market softness has created headwinds for our business."
The significant stock decline indicates investors’ concerns about the company’s near-term growth prospects as it navigates through these market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.